ResMed Inc.
In the published model solve dated 2026-Q2, anchored at $240.33, ResMed Inc. (RMD) is priced for +11.3% growth. boothcheck publishes no house fair value, target price, or buy/sell rating; individual model outputs and user-controlled scenarios are analytical inputs, not Boothcheck targets. The narrative was composed June 28, 2026 from SEC EDGAR filings.
• ResMed is the leader in sleep-apnea care, selling flow-generator devices and, more importantly, the masks and accessories patients replace on a recurring basis, with a growing Residential Care Software arm layered on top. • The recurring-revenue model is the moat: masks and accessories grew 12 percent globally last quarter and the consumables base resets demand every year, which is why the price implies only modest operating growth of about 4 percent a year rather than a heroic assumption. • W
Is RMD overvalued? See what's priced in →
904 institutional managers reported holding RMD in 13F filings for the quarter ended 2026-03-31. Together they hold about 66% of the company; the top 10 hold 39%. 85 opened new positions that quarter. Held by Vanguard Group, BlackRock, State Street, among others. On the short side, 12.9M shares were sold short as of the 2026-06-15 count, about 9% of shares outstanding (9 days of typical volume to cover).
Quarterly 13F filings arrive up to 45 days after quarter end, so the picture is never current (filed through 2026-05-29). Nothing here is investment advice.
RMD's share count is about flat over the past five years ($950.07M of repurchases, offset by issuance). It pays a dividend, and has for 14 years running, raised 13 years straight; the current rate is $2.12 a share annually. Cash returned over the past three years: $855.77M in dividends and $950.07M in repurchases.
Share counts are split-adjusted; repurchase totals are gross of share issuance. Nothing here is investment advice.
No open-market insider buys on file at RMD over the trailing three years. Absence is a fact about the company, not a signal. 16 officers and directors are on file.
Code P open-market purchases from SEC Form 4 filings, non-derivative, excluding scheduled 10b5-1 plans. Nothing here is investment advice.
RMD's recent reports: the day-one move, then what the following quarter actually did.
| report | day one | next quarter |
|---|---|---|
| 2023-08-12 | -19.3% | -21.9% |
| 2023-10-28 | -4.2% | +27.8% |
| 2024-01-26 | +6.5% | +4.1% |
| 2024-04-27 | +18.6% | -12.2% |
Day-one is the close-to-close move around the filing. Nothing here is investment advice.
RMD's latest 8-K filings: 2026-08-17 (items 4.01, 5.02, 7.01, 9.01); 2026-08-06 (items 2.02, 8.01, 9.01); 2026-07-07 (items 2.02, 7.01, 9.01); 2026-04-30 (items 5.02, 9.01); 2026-04-30 (items 2.02, 8.01, 9.01).
Item codes are the SEC's own classification of what each report discloses. Dates link to the filing on EDGAR. Nothing here is investment advice.
Model solve date: 2026-Q2
Narrative composed: June 28, 2026
Each week boothcheck ranks the stocks whose prices are betting on the most. Read the most stretched bets archive →
boothcheck is also on Android. Get the app on Google Play →
For informational and research purposes only. Not investment advice. Not a recommendation to buy, sell, or hold any security. boothcheck is not a registered investment adviser. Past performance does not guarantee future results.